

Drug discovery
2
drugs
With orphan designations
Overview
Hereditary orotic aciduria (HOA) is a rare autosomal recessive disorder caused by deficiency of uridine monophosphate synthase (UMPS), disrupting de novo pyrimidine synthesis. It presents with megaloblastic anemia, growth retardation, developmental delay, and excessive urinary orotic acid excretion, which may lead to crystalluria and urinary obstruction. Untreated cases risk irreversible neurodevelopmental disabilities. Diagnosis relies on elevated urine orotic acid, genetic testing for UMPS mutations, and exclusion of urea cycle defects. Early treatment with uridine supplementation (e.g., uridine triacetate) prevents complications [1][7][11][14].
Burden
Untreated cases develop refractory anemia, immunodeficiency, and severe intellectual disability [1][11].
Chronic crystalluria increases risk of nephrolithiasis and obstructive uropathy [7][9].
High economic burden due to orphan drug costs ($22,500/30 packets for Xuriden) and lifelong management [3][8].
Therapies
Uridine triacetate (Xuriden): FDA-approved oral therapy (60–120 mg/kg/day) to bypass UMPS deficiency, restoring pyrimidine levels and preventing anemia/neurodevelopmental sequelae [3][8][16].
Lifelong therapy required; early initiation critical for optimal outcomes [14][18].
No established alternative treatments; hematologic monitoring and genetic counseling recommended [1][7].
Categories: rare genetic diseases, rare hematological diseases, rare inborn errors of metabolism, rare neurological diseases
Drug Discovery Landscape
Drug | Therapy type | Orphan designation | Clinical trial status | Sponsor |
|---|---|---|---|---|
Uridine triacetate | small molecules | EMA | Serb | |
uridine triacetate | small molecules | FDA | Approved | BTG International Inc. |
“Terminated” – programs with discontinued clinical trials, or with no updates reported for 5 years after completion or 12 years after the last trial started.